

Mangalam Drugs and Organics Ltd.

Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.
☎ 91-22-22616200 / 6300 / 8787 ☎ 91-22-22619090 • CIN : L24230MH1972PLC116413



REF: MDOL/CS-SE/2019-20/037

January 24, 2020

To,
Listing Department
BSE Ltd
1st Floor, New Trade Wing,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001.
Scrip Code: 532637

Listing Department
National Stock Exchange of India Limited
“Exchange Plaza”, 5th Floor,
Plot No. C-1, Block G,
Bandra - Kurla Complex,
Bandra(E), Mumbai – 400 051
Symbol: MANGALAM

Sub: Outcome of the Board Meeting held on Friday, January 24, 2020

Dear Sir / Madam,

In terms of Regulation 30 read with part A of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (the Listing Regulations), we have to inform you that the Board of Directors of the Company, in their meeting held today i.e. Friday, January 24, 2020 has *inter-alia* approved the Un-Audited Financial Results for the quarter and nine months ended December 31, 2019 along with the Limited Review Report on the results pursuant to Regulation 33 of the Listing Regulations.


The meeting of Board of Directors commenced at 2:30 P.M. and concluded at 3:40 P.M.

We request you to take the same on your records.

Thanking You,

Yours faithfully,
For Mangalam Drugs & Organics Limited

Geeta Karira



Geeta Karira
Company Secretary & Compliance officer

Un-Audited Financial Results for the Quarter & Nine Months Ended 31st December 2019 approved and taken on record by the Board at their meeting dated 24th January, 2020

Sr.No	Particulars	Quarter Ended			Year to Date		(Rs. In Lac.) Year Ended
		31.12.2019	30.09.2019	31.12.2018	31.12.2019	31.12.2018	31.03.2019
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
A) Part-1 Statement of Un-Audited Financial Results for the Quarter & Nine Months Ended December 31, 2019							
1	Revenue from Operations	6,194.36	6,727.31	4,858.28	19,425.90	17,949.06	22,757.97
2	Other Income	65.90	3.02	4.54	72.79	11.15	31.68
3	Total Revenue(1+2)	6,260.26	6,730.33	4,862.82	19,498.69	17,960.21	22,789.65
4	Expenses						
	(a) Cost of Materials Consumed	3,744.41	4,566.24	3,951.23	12,527.59	13,133.21	16,870.28
	(b) Purchase of Stock in trade	0.00	0.00	0.00	0.00	0.00	0.00
	(c) Changes in Inventories of Finished Goods, Stock-in-trade & Work in progress	408.34	57.02	(784.01)	643.45	(1,357.20)	(1,538.93)
	(d) Employee Benefits Expenses	635.28	658.60	636.77	1,898.75	1,933.65	2,581.65
	(e) Finance Costs	254.45	274.60	229.53	794.18	612.11	864.65
	(f) Depreciation & amortization expenses	205.75	226.50	183.49	612.17	543.15	708.85
	(g) Other Expenses	910.46	833.39	1,153.61	2,702.70	3,297.65	3,876.85
	Total Expenses	6,158.69	6,616.36	5,370.62	19,178.84	18,162.57	23,363.35
5	Profit / (Loss) before exceptional & extraordinary items and tax(3-4)	101.57	113.97	(507.80)	319.85	(202.36)	(573.71)
6	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
7	Profit/(Loss) before extraordinary items and tax (5-6)	101.57	113.97	(507.80)	319.85	(202.36)	(573.71)
8	Extraordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
9	Profit(+)/Loss (-) before tax(7-8)	101.57	113.97	(507.80)	319.85	(202.36)	(573.71)
10	Tax Expenses						
	Current Tax	11.85	33.18	(65.82)	75.41	0.00	0.00
	Less: MAT credit entitlement / reversal	(75.41)	0.00	0.00	(75.41)	0.00	0.00
	Deferred Tax	0.00	0.00	0.00	0.00	0.00	229.38
11	Net Profit(+)/Loss(-) after Tax (9-10)	165.13	80.79	(441.98)	319.85	(202.36)	(803.09)
12	Other Comprehensive income not reclassified into Profit & loss account (Net of Taxes)	0.87	0.61	0.41	2.00	1.26	1.69
13	Total Comprehensive Income	166.00	81.40	(441.57)	321.85	(201.10)	(801.40)
14	Paid-up Equity Share Capital (face value of Rs 10/- each)	1,582.82	1,582.82	1,582.82	1,582.82	1,582.82	1,582.82
15	Other Equity						7,992.80
16	Earnings Per Share (EPS) (of Rs 10/-each)not annualised):						
	(a) Basic	1.04	0.51	(2.79)	2.02	(1.28)	(5.07)
	(b) Diluted	1.04	0.51	(2.79)	2.02	(1.28)	(5.07)

Notes :

- The above results have been prepared in accordance with Indian Accounting Standard (Ind AS) notified under section 133 of the companies Act 2013, read together with Companies (Indian Accounting Standard) Rules, 2015.
- The above results have been reviewed by the Audit Committee and thereafter, were approved & taken on record by the Board of Directors of the Company at their meeting held on January 24, 2020. The Statutory Auditors have expressed an modified audit opinion on these financial result.
- As the Company's business activity falls within a single primary Business Segment Viz. "Manufacturing of Bulk Drugs" and hence does not have any additional disclosure to be made under Ind AS-108 on "Operating Segments".
- Deferred Tax calculation as per Ind AS 12 is considered by the Company on annual basis
- Earlier period figures have been regrouped/ rearranged wherever necessary.

FOR BATLIBOI & PUROHIT
CHARTERED ACCOUNTANTS

Place: Mumbai
Date: 24th January, 2020

(R. L. HANGEKAR)
PARTNER
MEMBERSHIP NO. 30615

On behalf of Board of Directors
For Mangalam Drugs & Organics Ltd

(Shri Govardhan M. Dhoot)
Chairman & Managing Director
(DIN:01240086)



Auditor's Review Report on Quarterly and Nine Months Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

**TO THE BOARD OF DIRECTORS OF
MANGALAM DRUGS & ORGANICS LIMITED**

We have reviewed the quarterly financial results of **MANGALAM DRUGS & ORGANICS LIMITED** for the quarter and nine months ended 31st December 2019 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. These financial results are based on the standalone financial statements for the quarter ended and nine months December 31, 2019 prepared in accordance with the accounting principal generally accepted in India, including "Ind AS" in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) for Interim Financial Reporting, prescribed, under Section 133 of the Companies Act, 2013, which are the responsibility of the Company's management.

This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to the financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Basis for qualified conclusion:

Based on our review and information and explanation provided to us by management, deferred tax as per Ind AS 12 is considered on an annual basis and hence impact of the same is not ascertainable on the Profit & Loss A/c and Assets and liabilities as on 31.12.2019.




BRANCHES :

NAVI MUMBAI : 302 / 304 Arenja Corner, Sector 17, Vashi, Navi Mumbai - 400 703. • Tel. : +91-22-2766 6478
DELHI : 505, Nirmal Tower, 26, Barakhamba Road, New Delhi -110 001. • Tel. : +91-11-4019 0200

Qualified Conclusion:

Based on our review conducted as above, with the exception of the matter described in the preceding paragraph, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Accounting Standards as notified under the Companies (Indian Accounting Standards) Rules, 2015 and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Batliboi & Purohit
Chartered Accountants
Firm Registration No: 101048W



Raman Hangekar
Partner
Membership No: 030615
UDIN: 20030615AAAAAJ9620



Place: Mumbai
Date: January 24, 2019